Natriuretic Peptide Testing in Primary Care

Shafiq U. Rehman and James L. Januzzi, Jr.*

Abstract: The incidence, as well as the morbidity and mortality associated with heart failure (HF) continue to rise despite advances in diagnostics and therapeutics. A recent advance in the diagnostic and therapeutic approach to HF is the use of natriuretic peptide (NP) testing, including both B-type natriuretic peptide (BNP) and its amino terminal cleavage equivalent (NT-proBNP). NPs may be elevated at an early stage among those with symptoms as well among those without. The optimal approach for applying NP testing in general populations is to select the target population and optimal cut off values carefully. Superior diagnostic performance is observed among those with higher baseline risk (such as hypertensives or diabetics). As well, unlike for acute HF, the cut off value for outpatient testing for BNP is 20-40 pg/mL and for NT-proBNP it is 100-150 ng/L. In symptomatic primary care patients, both BNP and NT-proBNP serve as excellent tools for excluding HF based on their excellent negative predictive values and their use may be cost effective. Among those with established HF, it is logical to assume that titration of treatment to achieve lower NPs levels may be advantageous. There are several ongoing trials looking at that prospect.

INTRODUCTION

Heart failure (HF) is a major and growing public health problem in the United States. The prevalence of HF in US is estimated around 5 million, and over 550 000 new cases are diagnosed with HF each year [1]. HF is the primary reason for 12 to 15 million office visits and 6.5 million hospital days each year. The incidence, as well as the morbidity and mortality associated with HF continues to rise despite advances in diagnostics and therapeutics [2]; this is in part due to the fact that ‘salvage’ of patients with myocardial infarction is in part more successful, but also reflects the age-related increase in the incidence of risk factors for HF, such as hypertension. In addition, there is an equally large pool of patients with myocardial dysfunction but without apparent HF symptoms, or at worst, minor symptoms. This further complicates decision making, revealing inadequacy of clinical means alone to recognize HF [3].

In addition to the diagnostic challenges, the timing and sequence of initiating treatments, gauging adequacy of therapy and monitoring of therapy for adverse events are significant challenges. Due to these factors the current care of patients with HF remains suboptimal [4] and many HF patients are hospitalized routinely for reasons that can be averted with good outpatient care [5].

A recent advance in the diagnostic and therapeutic approach to HF is the use of natriuretic peptide testing. Including both B-type natriuretic peptide (BNP) and its amino terminal cleavage equivalent (NT-proBNP), this class of biomarker has proven to be more useful than original expectations. This review will discuss recent advances in the use of natriuretic peptide testing to assist in the primary care recognition and management of patients with suspected or proven HF.

Heart Failure as a Progressive Disorder

HF is a progressive disorder accompanied with changes in left ventricular (LV) structure and geometry such that the chamber dilates and/or hypertrophies and becomes more spherical—a process referred to as cardiac remodeling. This change further deteriorates myocardial function which in turn perpetuates the remodeling process. Cardiac remodeling generally precedes the development of symptoms (occasionally by months or even years) and may continue despite treatment.

Several factors can accelerate the process of LV remodeling, of these the activation of endogenous neurohormonal systems plays a vital role in cardiac remodeling and thereby in the progression of HF. Because natriuretic peptides (NPs) are produced in the heart, they may serve as a biological marker of LV remodeling and changes in circulating NPs may parallel the changes in LV structure [6-8].

BIOLOGY OF BNP AND NT-proBNP

Synthesis, Release and Physiological Actions

Human BNP is synthesized as a pre-pro-peptide which is cleaved by endoprotease yielding a 108-amino-acid propeptide (proBNP1-108) [9]. The propeptide is further cleaved by a furin- or corin-like endoprotease [10] to form biologically active BNP and inactive N-terminal proBNP. Both of these peptides circulate in human plasma [11].

Multiple mechanisms induce the BNP gene, however, mechanical stretch is probably the most potent inducer of the BNP gene expression in cardiac myocytes [12]. In addition to myocytes, cardiac fibroblasts and the coronary vasculature have also been shown to express the BNP gene [13,14]. While BNP mRNA concentrations are higher in the atria than the ventricles [9], given the greater ventricular mass, total content of BNP mRNA is greater in the ventricle [15]; thus the ventricles are the main determinants of serum concentration of BNP under both physiologic and pathological conditions [16,17]. Besides stretch, additional stimuli for BNP release have been proposed including endotoxemia [18], hypoxia [19], and ischemia [20].

While BNP may have several endocrine functions including vasodilation, natriuresis, inhibition of the sympathetic nervous as well as the renin-angiotensin aldosterone system
ject to the effects of biological variability than BNP, the sig-
therapeutic monitoring. While NT-proBNP appears less sub-
true" change, and may be interpretable in the context of
BNP or NT-proBNP in the range of 25-30% likely reflects a
much less subject to wide biologic variability and appears
peptide levels is in the order of 30%, with a change of more
patients, long-term intra-individual variation in natriuretic
splicing of BNP and/or NT-proBNP may also contribute to
and contractility [20, 22]. NT-proBNP, on the other
hand is considered biologically inert [23], but its elevation
nonetheless reflects activity of the BNP gene, and NT-
proBNP appears to provide comparable information to BNP
in most circumstances.

Circulating Concentrations of Natriuretic Peptides

Plasma concentrations of both NPs (BNP and NT-
proBNP) in healthy persons are much lower than in diseased states, are quite comparable to each other (unlike in disease states), and are more modified by physiologic factors including age, gender and drugs than in the disease state.

NPs increase with age [24], probably related to the more frequent occurrence of systolic, and diastolic dysfunction and ventricular hypertrophy in the elderly, as well as the drop in renal function (requisite for clearance of both peptides) seen with age [25]; NPs are higher in women [24], possibly due to estrogen levels in women in reproductive age [26] or effects of androgens in men, leading to lower values in males [27]. Circadian variation may be seen in BNP/NT-
proBNP concentrations, although these levels are small and clinically insignificant [28].

The effects of drugs on circulating NP concentrations are complex. Cardiovascular drugs with favorable effects on the neurohormonal system such as diuretics, angiotensin-converting enzyme inhibitors, β-adrenergic blockers, and spironolactone may lower NP values, in parallel with the improved prognosis seen with treatment with these drugs [29-52].

Biological Variability

The biological variation of NPs secretion must be considered when interpreting serial natriuretic peptide results. Biological variability refers to the expected day-to-day or week-to-week changes in NPs levels measured in apparently stable patients in response to physiologic changes such as changes vascular tone and filling pressures, without overt de-
stabilization [53-55], as well as possibly changes in clearance as well [56]. In addition, analytical imprecision and alternate splicing of BNP and/or NT-proBNP may also contribute to variability in circulating levels [57, 58].

Recent studies suggest that in stable chronic heart failure patients, long-term intra-individual variation in natriuretic peptide levels is in the order of 30%, with a change of more than 23% likely to indicate a clinically significant change beyond background variation [59, 60]. NT-proBNP appears much less subject to wide biologic variability and appears relatively constant with variability that may be less than 10% [59].

In summary, considering biological variation, changes in BNP or NT-proBNP in the range of 25-30% likely reflects a “true” change, and may be interpretable in the context of therapeutic monitoring. While NT-proBNP appears less subject to the effects of biological variability than BNP, the sig-
nificance of this finding relative to the value for management of HF patients remains unclear.

Despite biological variability and conditions that modify NP levels, NPs remain potentially useful to discern a wide range of clinical conditions in HF patients. The applicability of natriuretic peptides is well accepted in inpatient care both in an emergency department setting as well as in a hospital-
ized patient with respect to diagnosis and prognosis, moreover, it has been found useful for screening, diagnosis and prognosis in outpatient care as well (Table 1).

Table 1: Clinical Uses of Natriuretic Peptides.

| Screening for HF in high risk populations |
| Prognostic evaluation in general population especially those with risk factor for heart disease. |
| Differentiation of HF from pulmonary conditions in dyspneic patients in primary care |
| Diagnosing HF in dyspneic patients in emergency department |
| Determining HF severity, Prognosis |
| Guiding HF therapy? |

CLINICAL APPLICATIONS OF NATRIURETIC PEPTIDES IN PRIMARY CARE

Screening for Asymptomatic Ventricular Dysfunction

The widespread use of echocardiography for screening purposes in general population is limited by its costs and lack of availability in primary care settings. NPs levels may provide an important tool in screening asymptomatic patients with LV dysfunction as NPs may be elevated in these patients from conditions that predispose to clinical HF including myocardial ischemia, inflammation, fibrosis, hypertro-
phy, and valvulopathy [19-22,65,66,]. The mechanisms of NPs elevation in these conditions at pre-clinical stage before accumulation of fluid and stretch of myocardium are thought to be related to their potential role in modulation of ventricu-
lar structure/remodeling/fibrosis. [22,65-67]. As it has been proposed that their synthesis is transcriptionally activated in response to the activation of rennin-angiotensin system and other neurohormonal pathways involved in heart failure.

Screening for asymptomatic LV dysfunction is particularly important as prevalence of asymptomatic LV systolic dysfunction alone is estimated from 0.9% to 12.9% [62], depending on baseline risk. Furthermore, among asymptomatic patients early detection of cardiac remodeling or related structural and functional impairment may allow preventive therapies to be initiated earlier delaying progression to HF [63, 64]. Moreover outcome data suggests that among general population, people with modest elevations in NPs are at increased risk for developing cardiovascular morbidity and mortality [68-70]. However, for accurate screening of sub clinical disease a clear delineation of the optimal cut off val-
ues and understanding of major cardiac (ischemia, arrhyth-
mia) and non cardiac (age, gender, obesity, anemia, renal function) sources of variation in NPs in the population is necessary. The natriuretic peptide cut points used in primary
care are considerably lower than for emergency department-based evaluation of acute dyspnea, and use of these higher cut points would be expected to result in reduced sensitivity of BNP or NT-proBNP. Indeed, as demonstrated by Tang and colleagues [61], the use of a BNP cut point of 100 pg/mL was associated with a disastrously low sensitivity among symptomatic HF patients in a HF/transplant clinic.

Among asymptomatic individuals in the community, NPs have been investigated for their ability to detect increased LV mass and impaired systolic and, or diastolic dysfunction. However, their performance relies on the characteristics determined by patient population. In a low risk population, lower pretest probability render NPs suboptimal for general screening of population [71-74], in addition, screening with NP’s may be cost prohibitive. In a study by Rosenfield et al., [71] BNP testing was found to be sub-optimal for screening patients with pre clinical systolic or diastolic dysfunction. Comparable results were reported in the Framingham Offspring Study by Vasan et al., [74], who observed suboptimal diagnostic accuracy of NPs for detection of mild left ventricular dysfunction (LVSD) (EF<50%) and LV mass especially among women. However, the diagnostic performance improved in women when moderate LSVD was targeted (EF <40%).

In contrast, use of NPs to screen select populations with higher risk for developing HF (including patients with coronary artery disease, hypertension, or diabetes mellitus who do not yet demonstrate impaired LV function, hypertrophy, or geometric chamber distortion, so called AHA stage A) may be advantageous.

It has been shown in population studies examining such patients that NP levels are generally higher in diabetics, hypertensives as well as those with increased LV mass [75]. These higher levels while prognostically relevant [76,77], may also be useful to identify those in whom targeted therapeutic intervention might be most appropriate.

Thus, depending upon the population investigated, there have been varying reports on the value of BNP for detecting LVSD in general populations (Table 2). Areas under the receiver operating characteristic (ROC) curve have ranged from 0.59 [78] to 0.95 [79], suggesting a potential utility in higher-risk, targeted groups, to identify cardiac abnormalities and thus trigger further work up and more intensive treatment.

From a perspective of modality of use, it is generally felt that the value of NP’s for widespread population screening is related to their negative predictive value (NPV), rather than their positive predictive value (PPV). That is, these assays are best used to exclude risk than to identify it. As an example, Epshteyn et al. [80] showed that in high risk asymptomatic diabetic population, BNP levels <39 pg/ml showed a high negative predictive value of 91%. In order to determine an appropriate BNP level which would preclude the need for echocardiography, it was shown that the cutoff point of 20 pg/mL had an impressive negative predictive value for those

Table 2. Use of Natriuretic Peptides for Screening in Low Risk and High Risk Population

| Cohort Type                        | Optimal Cut off Value | AUC | NPV | PPV |
|-----------------------------------|--------------------------------|-----|-----|-----|
| **Low Risk or General Population**|                               |     |     |     |
| Redfield et al. (EF ≤40% or moderate-to-severe diastolic dysfunction) | 25.9 pg/mL (BNP) | 0.79 | N/A | N/A |
| Vasan et al. EF ≤50 | | | | | |
| EF ≤50 | 45 pg/mL (BNP) | M=0.72 | 0.93 | 0.38 |
| 50 pg/mL | W=0.56 | 0.98 | 0.07 |
| EF ≤40 | 51 pg/mL (BNP) | M=0.79 | 0.97 | 0.22 |
| 50 pg/mL | W=0.85 | 1.00 | 0.04 |
| **High Risk or Symptomatic**      |                               |     |     |     |
| Gustedsson F et al. Systolic Dysfunction EF ≤0.40 | 125 pg/mL (NT-proBNP) | 0.87 | 0.99 | 0.15 |
| Faut et al. Systolic Dysfunction EF ≤0.40 | | | | | |
| 40 pg/mL (BNP) | 0.79 | 0.88 | 0.49 |
| 150 pg/mL (NT-proBNP) | 0.81 | 0.92 | 0.48 |
| Krishnaswamy P et al. Systolic or Diastolic Dysfunction | 48 pg/mL (BNP) | 0.95 | 0.85 | 0.90 |
| Lubien E et al. Diastolic Dysfunction | | | | | |
| 62 pg/mL (BNP) | 0.91 | 0.89 | 0.78 |
| Mak GS et al. Diastolic Dysfunction | | | | | |
| 90 pg/mL (BNP) | 0.89 | 0.98 | 0.36 |
with systolic dysfunction (96%) or systolic plus diastolic dysfunction (100%) [81]. Similarly, for NT-proBNP a cut-off value of 125 pg/mL had the sensitivity, specificity, positive predictive value, and negative predictive values of 0.97, 0.46, 0.15 and 0.99, respectively to detect LVSD (EF < 40). Area under the ROC curve was 0.87. The application of an age-differentiated cut-off value for NT-proBNP (125 pg/mL for <75 years old and 450 pg/mL for > 75 years old) did not increase diagnostic performance [82].

Utility of BNP testing for identifying any structural heart disease in addition to LV systolic dysfunction was assessed in another study [83] involving general population. In ROC analyses, the AUC was suboptimal (0.77; 95% CI=0.74-0.79) for general screening of structural heart diseases including mild left ventricular systolic dysfunction, valvular heart disease, hypertensive heart disease, hypertrophic cardiomyopathy, ischemic heart disease and lone atrial fibrillation. This efficacy was improved when select groups with a high prevalence of heart disease were considered. For instance, those older then 65 (men, AUC = 0.88; women, AUC = 0.83) as well as those with hypertension or diabetes (men, AUC = 0.85; women, AUC = 0.83). Similar results were reported earlier in another Japanese study where a plasma BNP level of 40 pg/ml had a sensitivity of 85% and a specificity of 92% for heart disease detection. AUC for BNP was significant 0.94 and a plasma BNP level of 13 pg/ml or less had a 100% NPV for heart disease [84].

In patients with isolated diastolic dysfunction, NPs may be elevated and may reflect the severity of dysfunction [85-89]. Moreover, BNP and NT-proBNP are elevated in those with mild diastolic dysfunction and correlate with increased filling pressures during exercise [90,91]. In a study by Lubien et al. [86], the area under the ROC curve for BNP to detect any diastolic dysfunction was 0.92 (0.87-0.95; p<0.001); patients with restrictive-like filling patterns on echocardiography had the highest BNP levels (408±66 pg/mL) and AUC =0.97 (Fig. 1). Importantly, however, while NP levels are unable to differentiate systolic vs. diastolic dysfunction [89] but in patients with symptoms of HF and normal systolic function, NP values may useful to predict diastolic abnormalities.

Importantly, even in the absence of overt HF, modest elevations in plasma NPs levels are prognostically meaningful in population-based testing. In a population-based prospective study of 1991 subjects without apparent heart failure both BNP and NT-proBNP were predictive of mortality after a median follow up of 5.6 years even after adjustment for clinical and echocardiographic abnormalities including left ventricular hypertrophy and diastolic dysfunction [92]; in this analysis, NT-proBNP was clearly superior to BNP for prognostication. In another prospective study of 3346 persons without heart failure, elevated BNP values above the 80th percentile (20 pg/mL for men and 23 pg/mL for women) were associated with multivariable-adjusted hazard ratios of 1.62 for death (P=0.02), 1.76 for a first major cardiovascular event (P=0.03), 1.91 for atrial fibrillation (P= 0.02), 1.99 for stroke or transient ischemic attack (P=0.02), and 3.07 for heart failure (P=0.002) [40]. Similarly, in another study of general population, McDonagh et al., showed that BNP was an independent predictor of 4-year all-cause mortality [93].

Overall, studies would thus suggest that the optimal approach for applying NP testing to detect HF or prognosticate in general populations is to select the target population carefully, with superior performance observed among patients with a higher baseline risk (such as hypertensives or diabetics). As well, unlike for acute HF, where higher decision limits are used, the cut off value for outpatient testing for BNP is 20-40 ng/mL and for NT-proBNP it is 100-150 ng/L. Values below these cut-points exclude the presence of cardiac abnormalities with a high NPV; values above these cut-points suggest further evaluation is necessary but do not absolutely guarantee the presence of cardiac structural abnormalities.

Diagnostic Evaluation in Symptomatic Patients

In symptomatic primary care patients, both BNP and NT-proBNP serve as excellent tools for excluding HF based on their excellent negative predictive values [94-100]. In patients with symptoms suggestive of HF, Cowie et al. [94] investigated the value of BNP and showed that a cut-off value of 22 pmol/L for BNP could rule out the diagnosis of HF with high NPV of 98%. Similarly, in a prospective, randomized controlled trial involving 305 patients with symptoms of dyspnea and/or peripheral edema, NT-proBNP measurement significantly improved the diagnostic accuracy by a general practitioner over and above clinical review by correctly ruling out heart failure [95]. In another study [96] (Fig. 2), NT-proBNP levels identified those with symptoms of heart failure and LVEF ≤40% among general population with a sensitivity of 92%, a specificity of 86%, negative pre-
dictive values of 100% and area under the curve of 0.94. Similarly in another study [97] both BNP and NT-proBNP had excellent negative predictive values for exclusion of HF in patients with clinical suspicion of HF; in this study, a BNP at a cut-off of 40 pg/ml had a NPV of 88%, and an NT-proBNP of 150 pg/ml gave a NPV of 92%.

Fig. (2). Receiver operating characteristic (ROC) curves for the ability of NT-proBNP to diagnose systolic HF and LVEF ≤ 50% ≤ 45% ≤ 40% ≤ 35%, respectively. For the diagnosis of heart failure ≤ 40, NT-proBNP = 106.7 pmol/l had sensitivity/specificity 0.92/0.86, positive predictive value /negative predictive value 0.11/1.00 and AUC = 0.94 Groenning BA et al. [96].

In a meta analysis involving 19 studies, 22 populations, authors suggested that in a low risk population appropriate use of NPs can help reduce the demands of echocardiography and cardiac referrals [99]. In a recent study [101], NT-proBNP use among symptomatic patients in general practice was found useful for cost-effective exclusion of the diagnosis of heart failure (HF).

Thus, in the presence of symptoms, a general recommendation would be to apply NP testing with the goal to exclude HF. Using cut-points of 20-40 pg/mL for BNP and 125-150 ng/L for NT-proBNP provides excellent NPV in this regard. Results above these levels do not necessarily confirm HF, but suggest that further evaluation is necessary (Fig. 3). Importantly, age exerts a significant effect on NP concentrations, thus, lower cut-points might be useful for younger patients, while higher cut-points (e.g. an NT-proBNP of 300-450 ng/L) might provide superior NPV for elders. The optimal cut-points for BNP in elders remain unclear.

Outpatient Measurement of NPs in Patients with Established HF

The longitudinal clinical assessment of stability (and hence prognosis) in HF is difficult because of the lack of strong predictors of mortality or morbidity. Plasma natriuretic peptide levels increase in patients with symptomatic HF in proportion to the severity of disease and correlate with several indices of heart failure such as the New York Heart Association (NYHA) functional class, hemodynamics, left ventricular ejection fraction and filling pressure [102-104]. In patients with chronic HF, plasma BNP and NT-proBNP predict functional capacity and exercise tolerance [105-108]. In terms of mortality NPs predict mortality across the entire spectrum of HF patients, in those patients with advanced disease as well as those with minimally symptomatic left ventricular dysfunction [109,110]. In fact, among plasma levels of ANP, BNP, cGMP, and norepinephrine and clinical and hemodynamic parameters, only high levels of plasma BNP (P<.0001) and pulmonary capillary wedge pressure (P=.003) were significant independent predictors of the mortality in patients with HF by Cox proportional hazard analysis [109]. Accordingly, a recent systematic review suggested that BNP is a strong prognostic indicator at all stages of disease and seems to be a better predictor of survival than many traditional factors, such as NYHA class, serum creatinine, and even left ventricular ejection fraction [110]. Moreover, BNP and NT-proBNP, were independently related to 4-year mortality in patients with severe heart failure receiving established heart failure therapy including angiotensin converting enzyme inhibitors and beta-blocker therapy [111].

While elevated baseline values of NPs are predictive of poorer outcomes, the prognostic value of the changing levels of BNP and NT-proBNP levels measured during treatment could be even more meaningful [112-115]. Furthermore, patients whose BNP values fail to fall in response to treatment tend to be at particularly high risk of death or a cardiovascular event [112,114,116,117]. Anand et al. [112] analyzed the significance of change in BNP over time from baseline to 4 and 12 months. While higher baseline values were predictive of morbidity and mortality, a further increase in BNP values over time led to further incremental rise in risk. On the other hand patients with the greatest percent decrease in BNP from baseline to 4 and 12 months had the lowest morbidity and mortality.

Because lower levels of BNP or NT-proBNP are associated with better clinical outcome, and patterns of NP concentrations appear to be more prognostic than single measurements, it is logical to assume that titration of treatment to achieve lower NPs levels may be advantageous. The logic behind this concept is that concentrations of NPs decrease following institution or intensification of several established therapies of HF; among these agents are diuretics, angiotensin re-
ceptor blockers (ARB), β blockers, spironolactone, and ne-

teride [29-52].

While levels of BNP and NT-proBNP fall parallel to the fall in filling pressures with institution of diuretics and vasodilators [29-36], it is interesting to note that initiation of non-loop diuretics with relatively modest diuretic effects such as spironolactone may lead to substantial acute and chronic reductions in BNP and NT-proBNP [38-42]. The acute fall may be related to a diuretic effect followed by more significant reductions in BNP or NT-proBNP related to the suggested benefits of spironolactone on ventricular remodeling [43]. Similarly, ACE inhibitors besides decreasing filling pressures [32-36], in addition they may have an anti remodeling related effect on natriuretic peptide levels. The response to β-blockers is more complex. Introduction of metoprolol in stable mild HF is associated with an initial rise in NT-proBNP levels that is related to its secretion (or clearance) but is not due to clinical decompensation [44, 45]. Longer-term following β-blocker therapy initiation or adjustment, levels of natriuretic peptides fall, paralleling changes in LV remodeling [45, 46]. The response of NT-

proBNP to carvedilol (and other vasodilator β-blockers) may be different from metoprolol, with an initial fall in natriuretic peptide levels [47-50]; since there were significant differences in the stages of HF of the studies comparing effects of β-blockers, these findings may be more due to different responses in NT-proBNP at different stages of HF, rather than heterogeneity in response to different agents.

The clinical benefit of titrating therapy according to NP levels was tested in a landmark study by Troughton et al. [118] patients with decompensated HF and ejection fractions of <40% were recruited to test the hypothesis that any treatment that decreases NT-proBNP levels to <200 pmol/L (approximately 1700 ng/L) would reduce cardiac events. Their results showed that NT-proBNP guidance resulted in fewer combined heart failure decompensation, hospitalization and mortality events (19 versus 54, p=0.02). More recently, findings supportive of natriuretic peptide guided HF therapy in context of a more contemporary HF regimen were demonstrated in the recently published STARS-BNP study [119]. In this multicenter study, 220 patients with NYHA functional class II–IV heart failure were randomized to BNP and clinically guided treatment. Therapies adjusted to achieve a BNP (target value<100 ng/L) resulted in more frequent changes 134 versus 66 in clinical group (p < 0.05); with all types of HF drugs changed more frequently in the BNP group. After a median 15 months follow up, the primary composite end point (unplanned hospital stays for heart failure or death related to heart failure) was observed in 25 of 110 (24%) in the BNP group versus 57 of 110 (52%) in the clinical group, (p < 0.001). Similarly, the STARBRITE study assessed the impact of targeting treatment to achieve an individualised BNP target during short-term follow-up [120]. While this strategy did not significantly reduce the number of days alive and out of hospital it did result in more optimal use of ACE inhibitor and β-blocker therapy, while diuretics were less likely to be increased.

The effect of guiding treatment to achieve targeted levels of NPs is currently being tested in several larger randomised trials. Methods papers have been published for the

REFERENCES

[1] Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 114: e85-151.

[2] Hunt SA. American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-82.

[3] Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-40.

[4] Redfield MM. Heart failure, an epidemic of uncertain proportions, N Engl J Med 2002; 346: 1442-4.

[5] Oddone EZ, Weinberger M, Horner M, et al. Classifying general medicine readmissions: are they preventable? Veterans Affairs Cooperateive Studies in Health Services Group on Primary Care and Hospital Readmissions. J Gen Intern Med 1996; 11: 597-607.

[6] Grybauskiene R, Karcevaikaita D, Brazdzionyte J, et al. Brain natriuretic peptide and other cardiac markers predicting left ventricular remodelling and function two years after myocardial infarction. Medicina (Kaunas) 2007; 43: 708-15.

[7] Giallauria F, Cirillo P, Luceri R, et al. Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N-terminal pro-brain natriuretic peptide. Eur J Cardiovasc Prev Rehabil 2008; 15: 113-118.

[8] White M, Rouleau JL, Hall C, et al. Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction. Am Heart J 2001; 142: 1056-64.

[9] Yandle TG. Biochemistry of natriuretic peptides, J Intern Med 1994; 235: 561-76.

[10] Sawada Y, Suda M, Yokoyama H, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endopeptidase furin. J Biol Chem 1997; 272: 20545-54.

[11] Hunt PJ, Yandle TG, Nicholls MG, et al. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995: 214: 1175-83.

[12] Kimmunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132: 1961-70.

[13] Tsuruda T, Boertriger G, Hunley BK, et al. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91: 1127-34.

[14] Casco VH, Veint JP, Kuroski de Bold ML, et al. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002; 50: 799-809.

[15] Ogawa Y, Nakao K, Mukoyama M, et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res 1991; 69: 491-500.
Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-12.

Hosoda K, Nakao K, Mukoyama M, et al. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 1991; 176 Pt 2: 1152-5.

Tomaru Ki K, Arai M, Yokoyama T, et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002; 34: 649-59.

Toth M, Vuorinen KH, Vuolteenaho O, et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardiun. Am J Physiol 1994; 266(4 Pt 2): H1572-80.

D’Souza SP, Baxter GF. B Type natriuretic peptide: A good omen in myocardial ischemia? Heart 2003; 89: 707-9.

Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I. Natriuretic peptides. J Hypertens 1992; 10: 907-12.

D’Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther 2004; 101: 113-20.

Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004; 50: 1503-10.

Wang TJ, Larson MG, Levy D, et al. Estradiol, progesterone and testosterone exposures affect the atrial natriuretic peptide gene expression in vivo in rats. Biol Chem Hoppe Seyler 1992; 373: 213-8.

Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. Am J Cardiol 2002; 90: 254-8.

Bosaeus I, Bjorén T, Agneta D, et al. Beneficial neurohumoral profile of spironolactone in severe congestive heart failure: results from the RALES neurohumoral substudy. J Am Coll Cardiol 2002; 40: 1596-601.

Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228-33.

Davies ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metropolol increases plasma B-type natriuretic peptides in mild, stable heart failure. Circulation 2006; 113: 977-85.

Mann JT, Kulik W, Simonetti D, et al. Effect of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000; 101: 378-84.

Cianfrone B, Frey B, et al. Effects of low dose beta-blockers on atrial and ventricular (B-type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995; 74: 502-7.

Hartmann F, Packer M, Coats AJ, et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004; 6: 343-50.

Richards AM, Doughty RN, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999; 99: 786-92.

Richards AM, Doughty RN, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37: 1781-7.

Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110: 1780-6.

Rademaker MT, Richards AM. Cardiac natriuretic peptide for cardiac health. Clin Sci (Lond) 2005; 109: 23-36.

Laufer L, Vollmann D, Drescher T, et al. Infracture monitoring to ct chronic heart failure deterioration: Relationship to changes in NT-proBNP. Eur J Heart Fail 2007; 9: 716-722.

Braunschweig F, Fährleiner-Pammer A, Mangiavacchi M, et al. Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. Eur J Heart Fail 2006; 8: 797-803.
Natriuretic Peptide Testing in Primary Care

B-type natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. Eur J Heart Fail 2006; 8: 797-803.

[56] Bruins S, Fokkema MR. High intra-individual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004; 50: 2052-8.

[57] Wu AH. Serial testing of B-type natriuretic peptide and NT-proBNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006; 152: 828-34.

[58] Lam CS, Burnett JC, Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2004; 43: 1677-84.

[59] Schoo M, Gustafsson F, Kjaer A, Hildebrandt PR. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur J Heart Fail 2007; 9: 177-82.

[60] Schoo M, Gustafsson F, Nielsen PH, Madsen LH, Kjaer A, Hildebrandt PR. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 2007; 9: 68-74.

[61] Tang WH, Girod JP, Lee MJ et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic systolic heart failure. Circulation 2003; 108: 2964-6.

[62] Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003; 138: 907-916.

[63] Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-91.

[64] MA Pfeffer, E Braunwald, LA Moye, et al. Effect of captopril on mortality in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial, N Engl J Med 1992; 327: 669-77.

[65] Kuhn M. Molecular physiology of natriuretic peptide signaling. Basic Res Cardiol 2004; 99: 76-82.

[66] Yellachich E, Zhuo D, Nandy P, Pandey KY. Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy. Physiol Genomics 2002; 72; 31: 193-202.

[67] Tsuruda T, Boerigter G, Huntey BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91: 1127-1134.

[68] Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-16.

[69] McKie PM, Rodeheffer RJ, Cataliotti A, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006; 47: 874-80.

[70] Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death; N Engl J Med 2004; 350: 655-63.

[71] Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC, Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004; 109: 3176-3181.

[72] Abhayaratna WP, Marwick TH, Becker NG, Jeffery IM, Mc Gill DA, Smith WT. Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. Am Heart J 2006; 152: 941-8.

[73] Heinonen PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004; 43: 1019-26.

[74] Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002; 288: 1252-9.

[75] Hildebrandt P, Boesen M, Olsen M, Wachtell K, Groenning B. N-terminal pro brain natriuretic peptide in arteriolar hypertension-a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004; 6: 313-7.

[76] Heart Protection Study Collaborative Group, Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 2007; 49: 311-9.

[77] Olsen MH, Wachtell K, Nielsen OW, et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: A LIFE substudy. J Hypertens 2006; 24: 153-9.

[78] Hetmanski DJ, Sparrow NJ, Curtis S, Cowley AJ. Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community. Heart 2000; 84: 440-1.

[79] Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, noninvasive diastolic dysfunction and assessment of prognosis in patients with diabetes. Diabetes Care 2003; 26: 2081-2087.

[80] Atisha D, Bhalla MA, Morrison LK, et al. A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction. Am Heart J 2004; 148: 518-23.

[81] Hilsted TF, Badskjaer JS. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected left heart failure. J Card Fail 2005; 11(Suppl): S15-20.

[82] Nakamura M, Tanaka F, Sato K, Segawa T, Nagano M. B-type natriuretic peptide testing for structural heart disease screening: a general population-based study. J Card Fail 2005; 11: 705-12.

[83] Ninnuma H, Nakamura M, Hiramori K. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology 1998; 90: 89-94.

[84] Mak GS, DeMaria A, Clapton P, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J 2004; 148: 895-902.

[85] Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-type natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Cardiol 2001; 87: 163-74.

[86] Tschöpe C, Kasner M, Westermann D, Tschöpe C, Kasner M, Westermann D, Tschöpe C, Kasner M, Westermann D, et al. Elevated NT-proBNP levels in patients with increased left ventricular filling pressure during exercise despite preserved systolic function. J Card Fail 2005; 11(Suppl): S28-33.

[87] Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003; 92: 1434-8.

[88] Krishnaswamy P, Lubien E, Clapton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274-9.

[89] Tschöpe C, Kasner M, Westermann D, et al. Elevated NT-ProBNP levels in patients with increased left ventricular filling pressure during exercise despite preserved systolic function. J Card Fail 2005; 11(Suppl): S28-33.

[90] McKeown PJ, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients undergoing echocardiography to determine left ventricular dysfunction. Am J Cardiol 2004; 94: 221-6.

[91] Krishnaswamy P, Lubien E, Clapton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274-9.

[92] Cowie MR, Struthers AD, Wood DA, et al. Plasma natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am J Cardiol 2004; 94: 221-6.

[93] Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. J Am Coll Cardiol 2003; 42: 1793-800.

[94] Groenning BA, Raymond I, Hildebrandt PR, et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by
plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004; 90: 297-303.

[97] Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006; 56: 327-33.

[98] Ephsteyn V, Morrison K, Krishnaswamy P, et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003; 26: 2081-7.

[99] Battaglia M, Pewsner D, Jüni P, Egger M, Bucher HC, Bachmann LM. Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: systematic review of test accuracy studies. Arch Intern Med 2006; 166: 1073-80.

[100] Doust JA, Glaziov-P, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004; 164: 1978-84.

[101] Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol 2008; 10: 25-8.

[102] Koglin J, Pehlivanli S, Schwablmaier M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38: 1934-1941.

[103] Groenning BA, Nilsson JC, Sondergaard L, et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro-brain natriuretic peptide concentrations. Am Heart J 2002; 143: 923-9.

[104] Jouzdani P, Funck F, Belloirni M, et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail 2003; 5: 155-60.

[105] Kruger S, Graf J, Kunz D, Stickel T, Hanprath H, Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 2002; 40: 718-22.

[106] Passino C, Poletti R, Bramanti F, Prontera C, Clerico A, Endin M. Neuro-hormonal activation predicts ventricular response to exercise and functional capacity in patients with heart failure. Eur J Heart Fail 2006; 8: 46-53.

[107] Vicenzini EL, Hager D, Barry MB, Kearney L, Ferrier A, Wu AH. Correlation of B-type natriuretic peptide level to 6-min walk test performance in patients with left ventricular systolic dysfunction. Clin Chir Acta 2003; 328: 87-90.

[108] Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-I. Eur Heart J 1999; 20: 1799-807.

[109] Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.

[110] Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure? systematic review. BMJ 2005; 330: 625.

[111] Stancek B, Frey B, Hulsman M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 436-42.

[112] Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-83.

[113] Koseki Y, Watanabe J, Shinozaki T, et al. Characteristics and 1-year prognosis of medically treated patients with chronic heart failure in Japan. Circ J 2003; 67: 431-6.

[114] Bettencourt P, Azevedo A, Pimenta J, Froes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168-74.

[115] Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110: 1780-6.

[116] Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-93.

[117] Ishii J, Cui W, Kitagawa F, et al. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 2003; 49: 2020-6.

[118] Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.

[119] Jouzdani P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49: 1733.

[120] Shah MR, Claes KA, Bowers MT, et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: Brain Natriuretic Peptide Versus the Clinical Congestion ScoreF (STARBRITE) trial. Am Heart J 2005; 150: 893-9.

[121] Lainchbury JG, Troughton RW, Frampton CM. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLISTICARRED" trial. Eur J Heart Fail 2006; 8: 532-8.

[122] Brunner-La Rocca HP, Buser PT, Schindler R. Management of elderly patients with congestive heart failure—design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 2006; 151: 949-55.